Skip to main content

Table 2 Therapeutic value of new drugs assessed with Ahlqvist-Rastad’s rating system

From: Assessment of the therapeutic value of new medicines marketed in Australia

Ahlqvist-Rastad’s rating system    N %
Drug for conditions with no currently available treatment A   0 0.0
Added therapeutic value* B B1 18 30.5
  B4 1 1.7
  Subtotal 19 32.2
Similar therapeutic value** C C1 5 8.5
  C2 20 33.9
  Subtotal 25 42.4
Inferior therapeutic value*** D D1 2 3.4
  D2 3 5.1
  Subtotal 5 8.5
Uncertain therapeutic value**** E   10 16.9
TOTAL    59 100.0
  1. *The effect (B1)/ safety (B2)/ dosage (B3)/ route of administration (B4) seems to be better for patients than that of previously licensed alternatives.
  2. ** First medicine of a new class of agents with similar therapeutic value to that of previously licensed alternatives (C1).
  3. New agent of an existing class with similar therapeutic value to that of previously licensed alternatives (C2).
  4. *** First medicine of a new class with inferior therapeutic value to that of previously licensed alternatives (D1).
  5. New agent of an existing class with inferior therapeutic value to that of previously licensed alternatives (D2).
  6. ****New agent whose therapeutic value remains unknown because evaluation is limited to its effects on surrogate end points.